TrialSignal
Clinical trial intelligence report
A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02658084
Status
TERMINATED
Phase
PHASE1
Sponsor
University of Miami
Executive brief
Investment-Ready Snapshot
The study proposes to evaluate the safety and efficacy of the combination of trastuzumab emtansine (T-DM1) and vinorelbine in HER2+ metastatic breast cancer patients.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02658084
Indication
Breast Cancer
Modality
small molecule
Target
Vinorelbine, Trastuzumab Emtansine
Intervention
Vinorelbine, Trastuzumab Emtansine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.